Skip to main content

Site navigation

  • University of Technology Sydney home
  • Home

    Home
  • For students

  • For industry

  • Research

Explore

  • Courses
  • Events
  • News
  • Stories
  • People

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt
  • Study at UTS

    • arrow_right_alt Find a course
    • arrow_right_alt Course areas
    • arrow_right_alt Undergraduate students
    • arrow_right_alt Postgraduate students
    • arrow_right_alt Research Masters and PhD
    • arrow_right_alt Online study and short courses
  • Student information

    • arrow_right_alt Current students
    • arrow_right_alt New UTS students
    • arrow_right_alt Graduates (Alumni)
    • arrow_right_alt High school students
    • arrow_right_alt Indigenous students
    • arrow_right_alt International students
  • Admissions

    • arrow_right_alt How to apply
    • arrow_right_alt Entry pathways
    • arrow_right_alt Eligibility
arrow_right_altVisit our hub for students

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Apply for a coursearrow_right_alt
  • Current studentsarrow_right_alt
  • Scholarshipsarrow_right_alt
  • Featured industries

    • arrow_right_alt Agriculture and food
    • arrow_right_alt Defence and space
    • arrow_right_alt Energy and transport
    • arrow_right_alt Government and policy
    • arrow_right_alt Health and medical
    • arrow_right_alt Corporate training
  • Explore

    • arrow_right_alt Tech Central
    • arrow_right_alt Case studies
    • arrow_right_alt Research
arrow_right_altVisit our hub for industry

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Find a UTS expertarrow_right_alt
  • Partner with usarrow_right_alt
  • Explore

    • arrow_right_alt Explore our research
    • arrow_right_alt Research centres and institutes
    • arrow_right_alt Graduate research
    • arrow_right_alt Research partnerships
arrow_right_altVisit our hub for research

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Find a UTS expertarrow_right_alt
  • Research centres and institutesarrow_right_alt
  • University of Technology Sydney home
Explore the University of Technology Sydney
Category Filters:
University of Technology Sydney home University of Technology Sydney home
  1. home
  2. arrow_forward_ios ... Newsroom
  3. arrow_forward_ios ... 2021
  4. arrow_forward_ios 08
  5. arrow_forward_ios A promising new treatment for COVID-19 infection

A promising new treatment for COVID-19 infection

2 August 2021

Getting back to nature to trial ways to improve critical care outcomes.

A pile of fennel seeds.

Seeds from the Nigella Sativa plant, better known as the Fennel Flower.

A flowering plant native to North Africa and Western Asia could be utilised in the future treatment of COVID-19 infection.

The seeds of the plant, Nigella Sativa, have been used for centuries as a traditional remedy for multiple medical conditions, including inflammation and infections.  Now, an Australian-first research review article has found it could be used to treat COVID-19.

“There is growing evidence from modelling studies that thymoquinone, an active ingredient of Nigella Sativa, more commonly known as the Fennel Flower, can stick to the COVID- 19 virus spike protein and stop the virus from causing a lung infection.

“It may also block the ‘cytokine’ storm that affects seriously ill patients who are hospitalised with COVID-19,” said Professor Kaneez Fatima Shad, lead author of a recently published comprehensive review article in the prestigious journal, Clinical and Experimental Pharmacology and Physiology.

Thymoquinone has been extensively studied in laboratories, including animal studies. These studies have shown that thymoquinone can moderate our immune system in a good way, by preventing pro-inflammation chemicals such as interleukins from been released.

This gives thymoquinone a potential role as a treatment for allergic conditions such as asthma, eczema, arthritis conditions including rheumatoid and osteoarthritis and even possibly multiple sclerosis.

The review paper provides insight into a natural product that has been used as a traditional remedy for over thousand years and may be finally receiving the recognition it deserves.

 Associate Professor Dennis Cordato

The review paper details the mechanisms of action of Nigella Sativa and thymoquinone and how they are a promising future treatment of COVID-19 infection.   There have been many barriers to the development of Nigella Sativa as a therapeutic agent in large part due to its poor natural gastrointestinal absorption.

“Advances in pharmacological development such as nanotechnology have seen the chance to overcome this barrier to enable for its use as an effective oral medication.

“Furthermore, the drug has recently been successfully given to patients as a nasal spray and topical paste,” said Dr Wissam Soubra, co-author.

Nigella Sativa has been shown to be helpful in treating high blood pressure, high cholesterol and diabetes mellitus. As an anti-inflammatory treatment, Nigella Sativa has also been found to help patients with allergic rhinitis and sinusitis, eczema, osteoarthritis and childhood epilepsy.

Nigella Sativa has also been proven to be effective in a laboratory environment in killing bacteria such as staphylococcus aureus that can cause a range of mild to severe infections if they enter the skin, and viruses including influenza.

“The review paper provides insight into a natural product that has been used as a traditional remedy for over thousand years and may be finally receiving the recognition it deserves,” said Associate Professor Dennis Cordato, co-author.

The study, The role of thymoquinone, a major constituent of Nigella sativa, in the treatment of inflammatory and infectious diseases, was recently published in the journal Clinical and Experimental Pharmacology and Physiology.

Share
Share this on Facebook Share this on Twitter Share this on LinkedIn
Back to Health and science

Related News

Acknowledgement of Country

UTS acknowledges the Gadigal People of the Eora Nation and the Boorooberongal People of the Dharug Nation upon whose ancestral lands our campuses now stand. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands. 

University of Technology Sydney

City Campus

15 Broadway, Ultimo, NSW 2007

Get in touch with UTS

Follow us

  • Instagram
  • LinkedIn
  • YouTube
  • Facebook

A member of

  • Australian Technology Network
Use arrow keys to navigate within each column of links. Press Tab to move between columns.

Study

  • Find a course
  • Undergraduate
  • Postgraduate
  • How to apply
  • Scholarships and prizes
  • International students
  • Campus maps
  • Accommodation

Engage

  • Find an expert
  • Industry
  • News
  • Events
  • Experience UTS
  • Research
  • Stories
  • Alumni

About

  • Who we are
  • Faculties
  • Learning and teaching
  • Sustainability
  • Initiatives
  • Equity, diversity and inclusion
  • Campus and locations
  • Awards and rankings
  • UTS governance

Staff and students

  • Current students
  • Help and support
  • Library
  • Policies
  • StaffConnect
  • Working at UTS
  • UTS Handbook
  • Contact us
  • Copyright © 2025
  • ABN: 77 257 686 961
  • CRICOS provider number: 00099F
  • TEQSA provider number: PRV12060
  • TEQSA category: Australian University
  • Privacy
  • Copyright
  • Disclaimer
  • Accessibility